Management of Thymectomized Myasthenic Patients

  • L. Fornádi
  • R. Horváth
  • A. Szobor


Up to now the exstirpation of thymus gland stands in the central position of the immuno-therapeutic strategy of myasthenia gravis promising alone the chance of total and definitive recovery in some cases. FIGURE 1. The current antigen-specific therapeutical approaches inducing autoimmune unresponsiveness to acetylcholin receptor are still in experimental phase.(ref. 1) They certainly need a rather long period until one or more of them will be applied in humans. This is the reason why the therapeutic centers elaborated new management for the therapy-resistant patients.(ref. 2, 3, 4, 5). FIGURE 2. In some dubious cases the diagnosis of myasthenia gravis and the indication of thymectomy are difficult and need a long-lasting observation. The benefit from maintaining anticholinesterase therapy, the significant respond to plasma-exchange in crisis, the secondary generalization of ocular symptoms and the electrodiagnostic tests becoming positive after some years all strengthen the indication for thymectomy. FIGURE 3. As you can see on the third figure the indication of immunotherapies other than thymectomy has pro- and contra-arguments. We used to apply these methods at thymectomy unresponders, elderly X-ray unresponders, pregnants in crisis-prone state and in anticholinesterase resistance or intolerance. The crisis tendency is the major reason for applying these expensive therapies, but decreasing the drug doses and making rare the myasthenic relapses in the interest of improving life-quality are not negligible standpoints, either. FIGURE 4. In some severe cases both the plasma-exchange and the high-dose intravenous methylprednisolon infusion as well as the repeated high-dose intravenous immunoglobulin therapy may unfortunately fail.(ref. 6, 7, 8) All these observations induced us preparing new effectual therapeutic pattern.


Total Recovery Intravenous Immunoglobulin Therapy Electrodiagnostic Test Myasthenic Patient Permanent Connection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Drachman D.B., K.R. Mclntosh, J. Reim, L. Balcer. 1993. Strategies for treatment of myasthenia gravis. Ann.N.Y.Acad.Sci. 681:515–528.PubMedCrossRefGoogle Scholar
  2. 2.
    Åhlberg R., Q. Yi, R. Pirskanen, G. Matell, C. Swerup, P. Rieber, G. Riethmüller, G. Holm, A.K. Lefvert. 1993. Clinical improvement of myasthenia gravis by treatment with a chimeric anti-CD-4 monoclonal antibody. Ann.N.Y.Acad.Sci. 681:552–555.PubMedCrossRefGoogle Scholar
  3. 3.
    Arsura E., N.G. Brunner, T. Namba, D. Grob. 1985. High-dose intravenous methylprednisolone in myasthenia gravis. Arch. Neurol. 42:1149–1153.Google Scholar
  4. 4.
    Devathasen G., Y.K. Kuch, P.N. Chong. 1984. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet. 2:809.Google Scholar
  5. 5.
    Fateh-Moghadam A., M. Wock, U. Besinger, R.G. Geursen. 1984. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet. 2:848.CrossRefGoogle Scholar
  6. 6.
    Fornádi L., R. Horváth, A. Szobor. 1991. Treatment with plasma-exchange. Experiences over ten years. Acta Med. Hung. 48:137–144.Google Scholar
  7. 7.
    Kornfeld P., S. Fox, K. Maier, M. Mahjoub. 1992. Ten years experience with therapeutic apheresis in a community hospital. J. Clin. Apher. 7:63–68.CrossRefGoogle Scholar
  8. 8.
    Fornádi L., R. Horváth, Z. Bárdosi, A. Szobor. 1994. Myasthenia gravis: effect of immunoactive therapies. Acta Med. Hung. 50:83–92.Google Scholar
  9. 9.
    Szobor A. 1990. Myasthenia gravis, pp. 120-143, 147-152, 154-189. Akadémiai kiadó, Budapest.Google Scholar
  10. 10.
    Szobor A., J. Molnár. 1990. Myasthenia gravis: results of thymectomy in 550 patients. Orv. Hetil. 131:2519–2527.Google Scholar
  11. 11.
    Szobor A. 1977. Pathomechanismen myasthenischer Krisenzustände. In: Schulze A.F., K. Seidel, S. Göllnitz (eds): Akute Krisenzustände und Notsituationen in der Neurologie und Psychiatrie. S. 7-10. Hirzel, Leipzig.Google Scholar
  12. 12.
    Cornelio F., C. Antozzi, R. Mantegazza, P. Confalonieri, E. Berta, D. Peluchetti, A. Sghirlanzoni, F. Fiacchino. 1993. Immunosuppressive treatments. Their efficacy on myasthenia gravis patients’ outcome and on the natural course of the disease. Ann. N.Y.Acad.Sci. 681:594–602.CrossRefGoogle Scholar
  13. 13.
    Vincent A., Z. Li, A. Hart, R. Barrett-Jolley, T. Yamamoto, J. Burges, D. Wray, N. Byne, P. Molenaar, J. Newsom-Davis. 1993. Seronegative myasthenia gravis. Evidence for plasma factor/s) interfering with acetylcholin-receptor function. Ann.N.Y.Acad.Sci. 681:529–538.PubMedCrossRefGoogle Scholar
  14. 14.
    Tindall R.S.A., J.T. Phillips, J.A. Rollins, L. Wells, K. Hall. 1993. A clinical therapeutic trial of Cyclosporine in myasthenia gravis. Ann.N.Y.Acad.Sci. 681:539–551.PubMedCrossRefGoogle Scholar
  15. 15.
    Tan E., M. Hajinazarian, W. Bay, J. Neff, J.R. Mendell. 1993. Acut renal failure resulting from intravenous immunoglobuline therapy. Arch. Neurol. 50:135–139.Google Scholar
  16. 16.
    Szobor A. 1976. Myasthenia gravis: A quantitative evaluation system. Disability Status Scale/DSS) applied for myasthenia gravis. Eur.Neurol. 14:439–446.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • L. Fornádi
    • 1
  • R. Horváth
    • 1
  • A. Szobor
    • 1
  1. 1.Neurological DepartmentJahn Ferenc-Teaching HospitalBudapestHungary

Personalised recommendations